Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Artelo Biosciences Inc (ARTL)

Artelo Biosciences Inc (ARTL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,130
  • Shares Outstanding, K 4,992
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,170 K
  • 60-Month Beta 1.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.69
Trade ARTL with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.05
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/23/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5900 +3.36%
on 10/15/20
1.5000 -59.35%
on 10/01/20
-0.2402 (-28.26%)
since 09/18/20
3-Month
0.5900 +3.36%
on 10/15/20
1.5000 -59.35%
on 10/01/20
-0.6377 (-51.12%)
since 07/17/20
52-Week
0.5900 +3.36%
on 10/15/20
4.4200 -86.20%
on 02/03/20
-1.7603 (-74.27%)
since 10/18/19

Most Recent Stories

More News
Artelo Biosciences, Inc. Announces Closing of $7.6 Million Underwritten Public Offering and Full Exercise of Underwriters' Option

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the...

ARTL : 0.6100 (-3.17%)
Artelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized Underwritten Public Offering

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the...

ARTL : 0.6100 (-3.17%)
Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced the receipt of Ethics...

ARTL : 0.6100 (-3.17%)
Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C....

ARTL : 0.6100 (-3.17%)
Artelo Biosciences to Participate in Two Keynote Panels at 3rd Annual International Cannabinoid Derived Pharmaceutical Summit

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive...

ARTL : 0.6100 (-3.17%)
NASDAQ Down Another 4% as Tech Selloff Continues

NASDAQ Down Another 4% as Tech Selloff Continues

ZBRA : 298.78 (+1.97%)
LRCX : 368.01 (+0.84%)
AAP : 156.20 (+0.78%)
UCTT : 24.55 (+2.38%)
RCL : 60.52 (+2.87%)
DLTR : 95.84 (+0.29%)
IRBT : 93.39 (+4.60%)
UFPI : 57.60 (+0.44%)
SCO : 15.94 (-0.99%)
YNDX : 58.62 (+1.09%)
MRVL : 42.77 (-0.44%)
NFLX : 531.29 (+0.09%)
VFC : 75.02 (-1.06%)
NKE : 129.35 (+1.05%)
BURL : 206.46 (-1.95%)
HTHT : 41.95 (+0.79%)
FIVE : 139.63 (+1.27%)
LVS : 46.03 (+1.45%)
ROST : 94.66 (-0.48%)
HBI : 17.19 (-0.06%)
MAXR : 31.48 (+7.26%)
MOS : 19.31 (+0.89%)
HOME : 22.02 (+1.15%)
BIG : 54.38 (+1.36%)
SPWH : 17.06 (+2.03%)
ARTL : 0.6100 (-3.17%)
AAPL : 119.49 (+0.39%)
LD Micro - 360 Companies Set to Present this Week

LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

ACRX : 1.8100 (-4.23%)
ACER : 2.90 (unch)
ACU : 25.79 (+5.31%)
AT.VN : 1.610 (-0.62%)
AEY : 2.10 (unch)
ADIL : 1.8400 (-2.13%)
ADTX : 2.12 (-3.64%)
ADXS : 0.4250 (+3.66%)
AEHR : 1.4700 (+1.38%)
AIM : 2.30 (+1.32%)
AIRI : 1.0761 (+0.57%)
ALIM : 4.75 (+1.71%)
ALJJ : 1.0100 (+4.45%)
ALLT : 10.17 (+0.89%)
ARCT : 55.06 (-0.13%)
AREC : 1.6400 (-4.65%)
AMS : 1.9143 (+0.75%)
ANVS : 4.91 (-1.41%)
APEN : 1.7450 (+2.05%)
APM : 2.65 (-3.99%)
AQMS : 0.9999 (+1.00%)
AQB : 4.43 (+0.45%)
ARTL : 0.6100 (-3.17%)
ARHH : 0.8017 (+0.20%)
ATOM : 10.07 (+2.55%)
ATOS : 2.03 (-3.79%)
AUTO : 4.19 (-0.71%)
AYRO : 2.93 (-3.30%)
AZRX : 0.7700 (+0.25%)
BELFA : 10.83 (+4.03%)
BCDA : 2.29 (-0.43%)
BIOC : 4.65 (-1.06%)
BHTG : 1.2800 (-2.29%)
BIOL : 0.3012 (-2.84%)
BKEP : 1.3350 (-2.55%)
ATDS : 0.0093 (+5.68%)
ASUR : 8.35 (+1.21%)
BEER.VN : 0.065 (-7.14%)
ANY : 1.7560 (+2.69%)
Artelo Biosciences to Present at The LD 500 Virtual Investor Conference on September 1st

LA JOLLA, CA / ACCESSWIRE / August 26, 2020 / (NASDAQ:ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be...

ARTL : 0.6100 (-3.17%)
LD Micro Announces Preliminary List of Presenters for the LD 500

LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

ACER : 2.90 (unch)
ACU : 25.79 (+5.31%)
AEY : 2.10 (unch)
ADIL : 1.8400 (-2.13%)
ADXS : 0.4250 (+3.66%)
AEHR : 1.4700 (+1.38%)
AIM : 2.30 (+1.32%)
AIRI : 1.0761 (+0.57%)
KERN : 4.42 (-0.23%)
ALIM : 4.75 (+1.71%)
ALLT : 10.17 (+0.89%)
AMS : 1.9143 (+0.75%)
ANVS : 4.91 (-1.41%)
APEN : 1.7450 (+2.05%)
APM : 2.65 (-3.99%)
AQB : 4.43 (+0.45%)
ARTL : 0.6100 (-3.17%)
ARHH : 0.8017 (+0.20%)
ATOM : 10.07 (+2.55%)
ATOS : 2.03 (-3.79%)
ACU.VN : 0.210 (-6.67%)
AUTO : 4.19 (-0.71%)
AYRO : 2.93 (-3.30%)
AYTU : 1.0000 (-2.91%)
AZRX : 0.7700 (+0.25%)
BLDP : 17.82 (-0.39%)
BELFA : 10.83 (+4.03%)
BCDA : 2.29 (-0.43%)
BIOC : 4.65 (-1.06%)
BMRA : 5.81 (-0.51%)
BSGM : 5.55 (-0.72%)
BLNK : 9.61 (-1.64%)
BKEP : 1.3350 (-2.55%)
CLBS : 1.7100 (+0.59%)
CLXT : 3.81 (-3.79%)
ASUR : 8.35 (+1.21%)
BLGO : 0.1510 (-0.26%)
Artelo Biosciences to Participate in BIO Digital and The Investor Summit Conferences

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system and related pathways, announced today that it will be...

ARTL : 0.6100 (-3.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Artelo Biosciences Inc. is a biopharmaceutical company. It is engaged in development and commercialization of proprietary therapeutics targeting the endocannabinoid system. The company's product pipeline consists of ART27.13, ART12.11 and ART26.12 which are in clinical stage. Artelo Biosciences Inc....

See More

Key Turning Points

2nd Resistance Point 0.6768
1st Resistance Point 0.6519
Last Price 0.6091
1st Support Level 0.6061
2nd Support Level 0.5852

See More

52-Week High 4.4200
Fibonacci 61.8% 2.9569
Fibonacci 50% 2.5050
Fibonacci 38.2% 2.0531
Last Price 0.6091
52-Week Low 0.5900

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar